Quince Therapeutics, Inc. 8-K/A

What Happened
Quince Therapeutics, Inc. (QNCX) filed a Current Report on Form 8-K/A on June 26, 2026 (Accession No. 0001193125-26-285572) disclosing a material modification to the rights of its security holders under Item 3.03. The filing states that the 8-K/A "amends and restates in its entirety" the previously filed report.

Key Details

• Filing type: Current Report on Form 8-K/A (amendment) filed June 26, 2026.
• Item reported: 3.03 — Material Modification to Rights of Security Holders.
• The amendment “amends and restates in its entirety” the earlier 8-K relating to this matter.
• Company/Ticker: Quince Therapeutics, Inc. (QNCX). Accession No.: 0001193125-26-285572.

Why It Matters
A material modification to security-holder rights can affect voting power, ownership interests, conversion or redemption features, or other protections for shareholders. Because the company has amended and restated the prior disclosure, investors should review the amended 8-K/A to understand the specific changes and their potential impact on holdings. For full details, consult the amended filing (accession number above) and any related exhibits, and consider contacting the company’s investor relations or a financial advisor.